Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 11.1%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 7,000 shares, an increase of 11.1% from the August 15th total of 6,300 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 9,300 shares, the days-to-cover ratio is presently 0.8 days.

Armata Pharmaceuticals Trading Up 1.8 %

NYSEAMERICAN:ARMP traded up $0.04 during trading hours on Wednesday, reaching $2.30. 809 shares of the company traded hands, compared to its average volume of 13,588. Armata Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $4.48. The stock has a market capitalization of $83.21 million, a price-to-earnings ratio of -1.01 and a beta of 0.79.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.13). As a group, equities research analysts predict that Armata Pharmaceuticals will post -1.02 EPS for the current year.

Institutional Trading of Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC lifted its holdings in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) by 80.8% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,777 shares of the company’s stock after purchasing an additional 14,647 shares during the period. SeaCrest Wealth Management LLC owned about 0.09% of Armata Pharmaceuticals worth $137,000 at the end of the most recent reporting period. 3.57% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday, August 15th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.